Sign in

Mitchell [Analyst]

Research Analyst at H.C. Wainwright

Mitchell Kapoor is the Director and Senior Biotechnology Analyst at H.C. Wainwright & Co., specializing in biotechnology and life sciences coverage. He has analyzed and provided actionable insights on a diverse portfolio of biotechnology companies, demonstrating expertise in evaluating both early-stage therapeutics and established firms. Kapoor began his career with foundational roles at Jefferies and Leerink Partners, then served as Assistant Vice President at Barclays Investment Bank before joining H.C. Wainwright in November 2021, where he was promoted to director. He holds an MBA from Cornell Johnson, an MS in Healthcare Policy & Research from Weill Cornell, and a BSBA from the University of Tennessee, and maintains FINRA Series 7, 63, 86, and 87 licenses.

Mitchell [Analyst]'s questions to CDXC leadership

Mitchell [Analyst]'s questions to CDXC leadership • Q2 2024

Question

The analyst, on behalf of Ram Selvaraju, asked about the pricing strategy and margin impact of NIAGEN IV, and the timeline for replacing NMN in international markets like China.

Answer

NIAGEN IV is priced slightly above existing NAD IV products and carries higher margins than the corporate average, which will be accretive to gross margin. In China, while NMN sales have plummeted due to regulatory changes, TRU NIAGEN has not yet seen a significant benefit as consumers are confused about the difference. The company is working on educating the market.

Ask Fintool Equity Research AI